Pirche

Pirche AG is a private, Leipzig-based company developing a sophisticated software platform for immunological risk assessment in transplantation and cell therapy. Its technology moves beyond traditional HLA matching to epitope-level analysis, aiming to minimize graft rejection and graft-versus-host disease. The company appears to be in a commercial or late-validation stage with its TxPredictor platform, which is integrated with major HLA lab software and is backed by extensive clinical validation across over 250,000 cases. Pirche is currently running a funding campaign to support its growth in the digital health and precision medicine space.

TxPredictor: A cloud-based, AI-supported software platform for digital epitope matching. It uses proprietary algorithms (PIRCHE for T-cell epitopes, Snow for B-cell epitopes) to predict immunological risk between donor and recipient by analyzing HLA typing data, enabling precise compatibility assessment for transplantation and cell therapy.

Pirche competes with traditional HLA typing services and laboratories that may offer basic epitope analysis. It likely faces competition from other specialized software companies and academic algorithms in the digital epitope matching space. Its competitive edge lies in its comprehensive, clinically validated, cloud-based platform with dual T- and B-cell epitope analysis and seamless lab integration.